Hypothyroidism, also known as underactive thyroid disease, is a disease caused by the inflammation of the thyroid gland. Some of the other causes of hypothyroidism may also include radiation therapy, thyroid surgery and pregnancy. The symptoms of hypothyroidism include constipation, low muscle tone, stomach bloating, swollen tongue and extreme sleepiness. According to the data published by the American Thyroid Association, more than 12% of the U.S. population will develop a thyroid condition during their lifetime. Hypothyroidism is more common among women as compared to men. Titan Pharmaceuticals, Inc. is in the process of developing T3 implant using its ProNeura drug delivery platform for continuous delivery of T3 for the treatment of hypothyroidism. ITL Pharma is also developing three drug candidates namely, TriThroid, BCT304 and combination of BCT305 and BCT306 for the treatment of hypothyroidism. Some of the companies having a pipeline of hypothyroidism include Titan Pharmaceuticals, Inc., ITL Pharma and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.